Editas Medicine to Participate in Upcoming Investor Conferences

GlobeNewswire

2024-11-06

CAMBRIDGE, Mass., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage gene editing company, today announced that management will participate in the following upcoming investor conferences in November and December:

Guggenheim’s Inaugural Healthcare Innovation Conference
Format: Fireside Chat
Date: Tuesday, November 12
Time: 4:00 p.m. ET
Location: Boston, MA

Stifel 2024 Healthcare Conference
Format: Fireside Chat
Date: Tuesday, November 19
Time: 1:50 p.m. ET
Location: New York, NY

7th Annual Evercore ISI HealthCONx Conference
Format: Fireside Chat
Date: Tuesday, December 3
Time: 1:20 p.m. ET
Location: Coral Gables, FL

To access the live webcasts of Editas Medicine’s presentations, please visit the “Investors” section of the Company’s website at www.editasmedicine.com. An archived replay will be available for approximately 30 days following each event.

About Editas Medicine
As a clinical-stage gene editing company, Editas Medicine is focused on translating the power and potential of the CRISPR/Cas12a and CRISPR/Cas9 genome editing systems into a robust pipeline of treatments for people living with serious diseases around the world. Editas Medicine aims to discover, develop, manufacture, and commercialize transformative, durable, precision genomic medicines for a broad class of diseases. Editas Medicine is the exclusive licensee of Broad Institute’s Cas12a patent estate and Broad Institute and Harvard University’s Cas9 patent estates for human medicines. For the latest information and scientific presentations, please visit www.editasmedicine.com.

CONTACT: Media and Investor Contact:
Cristi Barnett
(617) 401-0113
cristi.barnett@editasmed.com

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2481027586"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2481027586\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2481027586?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-11-06 22:00","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2481027586","market":"hk","top_or_hot":-1,"title":"Editas Medicine to Participate in Upcoming Investor Conferences","media":"GlobeNewswire","content":"<html><body><p>CAMBRIDGE, Mass., Nov.  06, 2024  (GLOBE NEWSWIRE) -- <a href=\"https://laohu8.com/S/EDIT\">Editas Medicine, Inc.</a> (Nasdaq: EDIT), a clinical-stage gene editing company, today announced that management will participate in the following upcoming investor conferences in November and December:</p> <ul type=\"disc\"><li><strong>Guggenheim’s Inaugural Healthcare Innovation Conference<br/></strong>Format: Fireside Chat<br/>Date: Tuesday, November 12<br/>Time: 4:00 p.m. ET<br/>Location: Boston, MA</li></ul> <ul type=\"disc\"><li><strong>Stifel 2024 Healthcare Conference</strong><br/>Format: Fireside Chat<br/>Date: Tuesday, November 19<br/>Time: 1:50 p.m. ET<br/>Location: New York, NY</li></ul> <ul type=\"disc\"><li><strong>7th Annual <a href=\"https://laohu8.com/S/EVR\">Evercore</a> ISI HealthCONx Conference<br/></strong>Format: Fireside Chat<br/>Date: Tuesday, December 3<br/>Time: 1:20 p.m. ET<br/>Location: Coral Gables, FL</li></ul> <p>To access the live webcasts of Editas Medicine’s presentations, please visit the “Investors” section of the Company’s website at www.editasmedicine.com. An archived replay will be available for approximately 30 days following each event.</p> <p><strong>About Editas Medicine</strong><br/>As a clinical-stage gene editing company, Editas Medicine is focused on translating the power and potential of the CRISPR/Cas12a and CRISPR/Cas9 genome editing systems into a robust pipeline of treatments for people living with serious diseases around the world. Editas Medicine aims to discover, develop, manufacture, and commercialize transformative, durable, precision genomic medicines for a broad class of diseases. Editas Medicine is the exclusive licensee of Broad Institute’s Cas12a patent estate and Broad Institute and Harvard University’s Cas9 patent estates for human medicines. For the latest information and scientific presentations, please visit www.editasmedicine.com.</p> <pre>CONTACT: Media and Investor Contact:\nCristi Barnett\n(617) 401-0113\ncristi.barnett@editasmed.com</pre> <br/><img referrerpolicy=\"no-referrer-when-downgrade\" src=\"https://ml.globenewswire.com/media/NGZjOGQ3MDYtMzUwNC00MjBkLTk4MTktMWVmZWEyNjUyNGM1LTEwMzc1OTk=/tiny/Editas-Medicine-Inc-.png\"/></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta content=\"text/html; charset=utf-8\" http-equiv=\"Content-Type\"/>\n<meta content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\" name=\"viewport\"/>\n<meta content=\"telephone=no,email=no,address=no\" name=\"format-detection\"/>\n<title>Editas Medicine to Participate in Upcoming Investor Conferences</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nEditas Medicine to Participate in Upcoming Investor Conferences\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1016364462\">\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/31bb960c88eab45f27ccc9fce75dee9a);background-size:cover;\"></div>\n<div class=\"h-content\">\n<p class=\"h-name\">GlobeNewswire </p>\n<p class=\"h-time smaller\">2024-11-06 22:00</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>CAMBRIDGE, Mass., Nov.  06, 2024  (GLOBE NEWSWIRE) -- <a href=\"https://laohu8.com/S/EDIT\">Editas Medicine, Inc.</a> (Nasdaq: EDIT), a clinical-stage gene editing company, today announced that management will participate in the following upcoming investor conferences in November and December:</p> <ul type=\"disc\"><li><strong>Guggenheim’s Inaugural Healthcare Innovation Conference<br/></strong>Format: Fireside Chat<br/>Date: Tuesday, November 12<br/>Time: 4:00 p.m. ET<br/>Location: Boston, MA</li></ul> <ul type=\"disc\"><li><strong>Stifel 2024 Healthcare Conference</strong><br/>Format: Fireside Chat<br/>Date: Tuesday, November 19<br/>Time: 1:50 p.m. ET<br/>Location: New York, NY</li></ul> <ul type=\"disc\"><li><strong>7th Annual <a href=\"https://laohu8.com/S/EVR\">Evercore</a> ISI HealthCONx Conference<br/></strong>Format: Fireside Chat<br/>Date: Tuesday, December 3<br/>Time: 1:20 p.m. ET<br/>Location: Coral Gables, FL</li></ul> <p>To access the live webcasts of Editas Medicine’s presentations, please visit the “Investors” section of the Company’s website at www.editasmedicine.com. An archived replay will be available for approximately 30 days following each event.</p> <p><strong>About Editas Medicine</strong><br/>As a clinical-stage gene editing company, Editas Medicine is focused on translating the power and potential of the CRISPR/Cas12a and CRISPR/Cas9 genome editing systems into a robust pipeline of treatments for people living with serious diseases around the world. Editas Medicine aims to discover, develop, manufacture, and commercialize transformative, durable, precision genomic medicines for a broad class of diseases. Editas Medicine is the exclusive licensee of Broad Institute’s Cas12a patent estate and Broad Institute and Harvard University’s Cas9 patent estates for human medicines. For the latest information and scientific presentations, please visit www.editasmedicine.com.</p> <pre>CONTACT: Media and Investor Contact:\nCristi Barnett\n(617) 401-0113\ncristi.barnett@editasmed.com</pre> <br/><img referrerpolicy=\"no-referrer-when-downgrade\" src=\"https://ml.globenewswire.com/media/NGZjOGQ3MDYtMzUwNC00MjBkLTk4MTktMWVmZWEyNjUyNGM1LTEwMzc1OTk=/tiny/Editas-Medicine-Inc-.png\"/>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4556","symbol_name":"基因編輯","start_time":0,"source_url":"https://www.globenewswire.com/news-release/2024/11/06/2975745/0/en/Editas-Medicine-to-Participate-in-Upcoming-Investor-Conferences.html","article_id":"2481027586","we_media_id":"1016364462","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2481027586","pubTimestamp":1730901600,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"GlobeNewswire","introduction":"Share your news with media, investors, and consumers with targeted distribution options from one of the world’s largest and most trusted newswires.","home_visible":1,"id":"1016364462","head_image":"https://static.tigerbbs.com/31bb960c88eab45f27ccc9fce75dee9a"},"summary":"Cristi Barnett. (617) 401-0113. cristi.barnett@editasmed.com","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4556":"基因编辑","BK4585":"ETF&股票定投概念","EDIT":"Editas Medicine, Inc.","BK4139":"生物科技","LU1861558580.USD":"日兴方舟颠覆性创新基金B","BK4588":"碎股","CRSP":"CRISPR Therapeutics AG","LU1861559042.SGD":"日兴方舟颠覆性创新基金B SGD"},"translate_title":"Editas Medicine将参加即将举行的投资者会议","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"EDIT":1,"CRSP":0.9},"content_text":"CAMBRIDGE, Mass., Nov.  06, 2024  (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage gene editing company, today announced that management will participate in the following upcoming investor conferences in November and December: Guggenheim’s Inaugural Healthcare Innovation ConferenceFormat: Fireside ChatDate: Tuesday, November 12Time: 4:00 p.m. ETLocation: Boston, MA Stifel 2024 Healthcare ConferenceFormat: Fireside ChatDate: Tuesday, November 19Time: 1:50 p.m. ETLocation: New York, NY 7th Annual Evercore ISI HealthCONx ConferenceFormat: Fireside ChatDate: Tuesday, December 3Time: 1:20 p.m. ETLocation: Coral Gables, FL To access the live webcasts of Editas Medicine’s presentations, please visit the “Investors” section of the Company’s website at www.editasmedicine.com. An archived replay will be available for approximately 30 days following each event. About Editas MedicineAs a clinical-stage gene editing company, Editas Medicine is focused on translating the power and potential of the CRISPR/Cas12a and CRISPR/Cas9 genome editing systems into a robust pipeline of treatments for people living with serious diseases around the world. Editas Medicine aims to discover, develop, manufacture, and commercialize transformative, durable, precision genomic medicines for a broad class of diseases. Editas Medicine is the exclusive licensee of Broad Institute’s Cas12a patent estate and Broad Institute and Harvard University’s Cas9 patent estates for human medicines. For the latest information and scientific presentations, please visit www.editasmedicine.com. CONTACT: Media and Investor Contact:\nCristi Barnett\n(617) 401-0113\ncristi.barnett@editasmed.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1}}}